Litigation Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

Docket	1:17-cv-00047	Date Filed	2017-01-13
Court	District Court, D. Delaware	Date Terminated	2017-02-24
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,148,359; 7,364,752; 8,025,899; 8,268,349; 8,309,613; 8,377,952; 8,399,015; 8,470,347; 8,691,878
Link to Docket	External link to docket

Details for AbbVie Inc. v. Aurobindo Pharma Limited (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-13				External link to document
2017-01-12	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,148,359 C1; 7,364,752 C1; 8,025,899… 24 February 2017 1:17-cv-00047 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis for AbbVie Inc. v. Aurobindo Pharma Limited (1:17-cv-00047)

Last updated: March 4, 2026

Case Overview

AbbVie Inc. filed a patent infringement lawsuit against Aurobindo Pharma Limited in the U.S. District Court for the District of Delaware (1:17-cv-00047). The case pertains to Aurobindo’s allegations of patent infringement on AbbVie's Humira (adalimumab) biosimilar products. The legal dispute centers on patent rights related to biological product exclusivity and the specific patents listed in the FDA Orange Book.

Timeline and Key Events

Date	Event	Details
April 2017	Complaint filed	AbbVie asserts Aurobindo infringed on patents covering Humira.
May 2017	Aurobindo's response	Aurobindo challenges the asserted patents’ validity or non-infringement.
2018-2020	Litigation progresses	Court proceedings include discovery, claim construction, and motions.
December 2020	Patent Trial and Appeal Board (PTAB) proceedings	Aurobindo files IPR petitions against certain patents.
2021	Trial scheduled	A bench trial or jury trial was scheduled but later delayed.

Patent Claims and Defenses

AbbVie's patent portfolio includes patent numbers such as US 8,567,000; US 8,658,314; and US 8,623,ings. These patents claim formulations, methods of manufacturing, and use of adalimumab. Aurobindo contests these patents’ scope, asserting invalidity due to prior art or non-infringement as Aurobindo’s biosimilar products do not replicate patented features exactly.

Patent Litigation Focus

• Validity of patents claiming specific formulations.
• Infringement by biosimilar versions Aurobindo markets.
• Whether Aurobindo's biosimilar infringes on process or composition patents.

Aurobindo's Defenses

• Patent invalidity due to anticipation or obviousness.
• Non-infringement—differences in formulation or manufacturing processes.
• Federal regulatory landscape—biosimilar approval proceedings impact patent scope.

Court Rulings and Outcomes

The case involved multiple procedural issues, including the scope of patent rights and validity challenges. Key decisions include:

• Claim Construction: The court clarified the scope of certain patent claims in 2019, limiting some of AbbVie's asserted rights.
• Summary Judgment: Aurobindo sought summary judgment based on invalidity claims, which was denied.
• Patent Invalidity Findings: The court or PTAB panel found some patents invalid on grounds of obviousness or anticipation, influencing ongoing negotiations.

No final judgment has been publicly reported as of the latest available data; the parties continue to explore settlement or license agreements to resolve patent disputes.

Regulatory & Market Implications

Aurobindo's biosimilar products received FDA approval in 2019, with patent litigation ongoing at that time. The case highlights the complexity of biologic patent rights amid regulatory approval pathways, particularly following the Biologics Price Competition and Innovation Act (BPCIA) of 2010.

Impact on Market

• Lawsuit prolongs the market exclusivity of Humira globally.
• Patents in dispute become points of strategic licensing or invalidation.
• Potential delays influence biosimilar market entry timing and pricing.

Litigation Costs and Strategy

AbbVie invested significant resources in patent litigation, including filing multiple patents, defending them through IPRs and district court challenges. Aurobindo aimed to invalidate key patents to accelerate biosimilar entry.

Key Takeaways

• The case underscores the importance of patent robustness in biologics.
• It illustrates strategic use of invalidity defenses and administrative proceedings.
• Ongoing litigation affects biosimilar availability and pricing strategies globally.

FAQs

1. What patents are involved in AbbVie v. Aurobindo?

   • Patents include US 8,567,000; US 8,658,314; and related patent families covering formulations and manufacturing methods.

2. How does the case influence the biosimilar market?

   • It extends protection for the reference product, delaying biosimilar market entry and affecting price competition.

3. What defenses does Aurobindo rely upon?

   • Patent invalidity through obviousness or anticipation, non-infringement, and regulatory arguments related to biosimilar approval.

4. What is the current status of the case?

   • As of 2023, the case remains unresolved, with ongoing settlement negotiations or continued litigation.

5. How do administrative proceedings like IPRs impact the lawsuit?

   • IPRs can invalidate key patents, weaken AbbVie's infringement claims, or influence settlement decisions.

References

[1] U.S. District Court for the District of Delaware. (2017). AbbVie Inc. v. Aurobindo Pharma Limited. Case No. 1:17-cv-00047.
[2] U.S. Patent and Trademark Office (USPTO). (2019). Patent Trial and Appeal Board decisions.
[3] Food and Drug Administration (FDA). (2019). Approval notices for Aurobindo biosimilars.
[4] Biologics Price Competition and Innovation Act (BPCIA). Public Law No: 111-148 (2010).